ClinicalTrials.gg
CompletedNCT03324776Updated Jun 26, 2024Results posted

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

A Phase 3 interventional study of Afrezza Inhalant Product in Type2 Diabetes, sponsored by Model Clinical Research LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Model Clinical Research LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
40th of 49
20 · median 129
Started
2017
with 1 other
Phase 3
25 of 49
none open now
Registered
45th of 49
by date

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 40th largest by enrollment, is one of 2 that started in 2017, is one of 25 in phase 3, and was the 45th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.

Read the detailed description

Clinical inertia in intensifying treatment of type 2 diabetes patients occurs in the range of 70% in numerous real world database assessments. The investigator proposes treating patients with Afrezza who have an index hemoglobin A1c (HbA1c) between 7.5% and 11.5% despite being treated with diabetes medications for at least 6 months. The response to Afrezza will be assessed with Continuous Glucose Monitoring Systems (CGMS) studies and initial and follow-up HbA1c's. The goal is to assess how the investigator can rapidly and safely initiate intensification in this patient population, where extensive delays in HbA1c improvement often occur.

03

Conditions studied

  • Type2 Diabetes

Keywords

  • inhaled insulin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult type 2 diabetes patients age 18 or older
  • ≥ 7.5% and ≤ 11.5% after at least 6 months treatment with diabetes medication. Treatment may include oral agents, basal insulin or Glucagon-like peptide-1 (GLP-1) in any combination.
  • Patient and provider agree not to add additional diabetes medications during the 14 weeks of the study (unless rescue treatment is indicated).

Exclusion criteria

Exclusion Criteria:

  • History of asthma, (COPD) or smoking within 6 months
  • (FEV1) under 70% predicted
  • Pregnancy
  • Active and/or of \< 12 months
  • Major surgery planned during study period
  • Currently using rapid acting insulins - Novolog, Humalog, Apidra
  • Prior use of Afrezza in the last 3 months
  • Unwilling to test blood glucose before or after each meal
  • Exposure to systemic within 6 weeks of screening
  • Severe hypoglycemia in last 6 months or hypoglycemia unawareness
  • Any medical condition which, in the opinion of the investigator, would interfere with ability to understand or respond to the administration of inhaled insulin
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    Addition of mealtime Afrezza Inhalation Powder

    Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm

    Drug: Afrezza Inhalant Product

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Percentage of HbA1c From Baseline to 3 Months

    Change in percentage of HbA1c from baseline to 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher and 11.5% or lower

    Time frame: Baseline to 3 months

Secondary outcomes

  1. Percentage of Patients With HbA1c Under 7% at 3 Months

    Percentage of patients with uncontrolled type 2 diabetes with HbA1c that is under 7% at 3 months

    Time frame: 3 months

  2. Percent of Time With Blood Glucose (BG) Under 70 mg/dL on CGMS

    Percent of time with BG under 70 mg/dL on CGMS at 3 months in participants with uncontrolled type 2 diabetes.

    Time frame: 3 months

07

Results

Posted Jun 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneAddition of Mealtime Afrezza Inhalation Powder
Started20
Completed20
Not completed0

Outcome measures

PrimaryChange in Percentage of HbA1c From Baseline to 3 Months

Change in percentage of HbA1c from baseline to 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher and 11.5% or lower

Time frame:
Baseline to 3 months
Reported as:
Mean · change in percentage of HbA1c
Change in Percentage of HbA1c From Baseline to 3 Months
change in percentage of HbA1cAddition of Mealtime Afrezza Inhalation Powder
Change in Percentage of HbA1c From Baseline to 3 Months1.6 ± 0.247
SecondaryPercentage of Patients With HbA1c Under 7% at 3 Months

Percentage of patients with uncontrolled type 2 diabetes with HbA1c that is under 7% at 3 months

Time frame:
3 months
Reported as:
Count of participants · Participants
Percentage of Patients With HbA1c Under 7% at 3 Months
ParticipantsAddition of Mealtime Afrezza Inhalation Powder
Percentage of Patients With HbA1c Under 7% at 3 Months4
SecondaryPercent of Time With Blood Glucose (BG) Under 70 mg/dL on CGMS

Percent of time with BG under 70 mg/dL on CGMS at 3 months in participants with uncontrolled type 2 diabetes.

Time frame:
3 months
Reported as:
Mean · percent of time with glucose <70mg/dL
Percent of Time With Blood Glucose (BG) Under 70 mg/dL on CGMS
percent of time with glucose <70mg/dLAddition of Mealtime Afrezza Inhalation Powder
Percent of Time With Blood Glucose (BG) Under 70 mg/dL on CGMS2.6 ± 2.5

Adverse events

Collected over 3.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Addition of Mealtime Afrezza Inhalation Powder0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Addition of Mealtime Afrezza Inhalation Powder
Mean61.4 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Addition of Mealtime Afrezza Inhalation Powder
Female7
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Addition of Mealtime Afrezza Inhalation Powder
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American7
White11
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Addition of Mealtime Afrezza Inhalation Powder
United States20
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(percentage of HbA1c)Addition of Mealtime Afrezza Inhalation Powder
Mean9.0 ± 0.94
Percent of Time Blood glucose (BG) under 70 mg/dL on Continuous Glucose Monitoring System (CGMS)
Percent of Time Blood glucose (BG) under 70 mg/dL on Continuous Glucose Monitoring System (CGMS)(percentage of time with glucose <70mg/dL)Addition of Mealtime Afrezza Inhalation Powder
Mean1.1 ± 2.3
08

Study locations

1 site
  • MODEL Clinical Research
    Baltimore, Maryland 21204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2020, 31 months.

Results were first posted in Jun 2024, 4 years after primary completion.

Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 31 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2017
First posted
Oct 30, 2017
StartActual
Oct 16, 2017
Primary completionActual
Jun 10, 2020
CompletionActual
Jun 10, 2020
Results first posted
Jun 26, 2024
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03324776
Lead sponsor
Model Clinical Research LLC
Responsible party
Philip Levin (Senior Director of Clinical Research, Model Clinical Research LLC) — Principal investigator
First posted
Oct 30, 2017
Start date
Oct 16, 2017
Primary completion
Jun 10, 2020
Completion
Jun 10, 2020
Results posted
Jun 26, 2024
Last update
Jun 26, 2024

Study contacts

Philip Levin, MD
principal investigator · Senior Director of MODEL Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion